Topic Code
HORIZON-HLTH-2025-03-IND-03-two-stage
F&T Portal
Call Identifier
HORIZON-HLTH-2025-03
Two stage (2025) — Stage 2
Instrument
HORIZON-RIA
Research and Innovation Action
Budget Model
Lump Sum
HORIZON-AG-LS
Funding Rate
100%
Annex G — RIA = 100%
Page Limit (Part B)
45 pages
RIA + lump sum — Stage 2
Evaluation Thresholds
4 / 4 / 4 · cum. 12
Non-standard — Stage 2 override
Expected Projects
5
€6–8M per project (WP stated)
Destination
Maintaining an innovative, sustainable, and competitive EU health industry
WP Part 4 (2025)
Cluster / Pillar
Cluster 1 / Pillar II
Health
China Eligibility
Eligible ✓
2025 WP: RIA not restricted
Special Conditions
Two-stage [Stage 2]
Stage 1: 16 Sep 2025 (closed)
This is a two-stage topic (Stage 2). Stage 1 closed 16 September 2025. Stage 2 deadline: 16 April 2026. Stage 1 page limit: 10 pages. Stage 2 page limit: 45 pages. Blind evaluation pilot applies to Stage 1.
This topic uses non-standard evaluation thresholds: Stage 2: 4 (Excellence) / 4 (Impact) / 4 (Implementation), cumulative 12. Standard thresholds are 3/3/3 cumulative 10.
Communication networks restriction: Entities assessed as high-risk suppliers of mobile network communication equipment (and entities they own or control) are not eligible to participate in this topic.
US entities eligible: In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, legal entities established in the United States of America are eligible to receive Union funding under this topic.
Copernicus/Galileo: If the project uses satellite-based earth observation, positioning, navigation and/or related timing data, beneficiaries must make use of Copernicus and/or Galileo/EGNOS.
Mandatory annex: Proposals under this topic are expected to include clinical studies. Applicants should provide details in the dedicated annex using the template provided in the submission system.
Expected Outcomes
- Healthcare providers increase their hands-on experience regarding the clinical use of orphan devices and/or of highly innovative (“breakthrough”) devices and get timely access to such devices with demonstrated clinical benefits.
- Developers and manufacturers collect and obtain scientific evidence on their proposed intervention/approach with the device under investigation.
- Patients benefit from the development, studies and use of orphan devices and/or of highly innovative (“breakthrough”) devices.
- Companies in the EU and associated countries get a better market position in this field and improve their knowledge on how to conduct multinational clinical studies for these devices.
Want the full analysis?
The key facts above tell you WHAT. The full Decision Brief tells you HOW to win.
Compliance traps
Scoring playbook
Consortium blueprint
Positioning guide
Red flags
Quick-start checklist
Order Full Brief — €79
Delivered within 1 working day